What do we need to make genetic biomarker-guided treatment for renal cell carcinoma a reality?

Meta H. Diekstra; Xiaoyan Liu; Jesse J. Swen; Henk-Jan Guchelaar

doi:10.2217/pgs-2016-0168

What do we need to make genetic biomarker-guided treatment for renal cell carcinoma a reality?

Meta H. Diekstra, Xiaoyan Liu, Jesse J. Swen, Henk-Jan Guchelaar^*

^*Corresponding author for this work

Research output: Contribution to journal › Editorial › Academic › peer-review

Original language	English
Pages (from-to)	1-4
Number of pages	4
Journal	Pharmacogenomics
Volume	18
Issue number	1
DOIs	https://doi.org/10.2217/pgs-2016-0168
Publication status	Published - Jan 2017

Keywords

biomarker
pharmacogenetics
renal cell carcinoma
SNP
targeted therapy
SUNITINIB
POLYMORPHISMS
PAZOPANIB
PHARMACOGENETICS
GUIDELINES
EVEROLIMUS
CANCER

Access to Document

10.2217/pgs-2016-0168

Cite this

@article{62b6563c4b034502ac305cb1a84c462d,

title = "What do we need to make genetic biomarker-guided treatment for renal cell carcinoma a reality?",

keywords = "biomarker, pharmacogenetics, renal cell carcinoma, SNP, targeted therapy, SUNITINIB, POLYMORPHISMS, PAZOPANIB, PHARMACOGENETICS, GUIDELINES, EVEROLIMUS, CANCER",

author = "Diekstra, {Meta H.} and Xiaoyan Liu and Swen, {Jesse J.} and Henk-Jan Guchelaar",

year = "2017",

month = jan,

doi = "10.2217/pgs-2016-0168",

language = "English",

volume = "18",

pages = "1--4",

journal = "Pharmacogenomics",

issn = "1462-2416",